FDA-Drug2026-04-01Class IIPROCESSING DEFECT

Teva Octreotide Acetate injectable suspension recalled for sterility assurance defect

OTHERNationwide distribution

Stop using recalled Teva Octreotide Acetate injections

Teva Pharmaceuticals is recalling specific lots of Octreotide Acetate 30 mg injectable suspension due to quality control problems found at the manufacturer. The FDA identified deficiencies that mean the sterility of these vials cannot be guaranteed. No injuries have been reported.

  • Check if you have one of the affected lot numbers (4400401, 4401393, 4401494, 4401604, 4500564, 4500601, 4500707, 4500796, 4500859, 4500918, 4500919, 4501006)
  • Do not use recalled vials; contact your pharmacist or doctor immediately
  • Ask your doctor or pharmacist for a replacement or alternative medication
  • Return unused vials to your pharmacy for proper disposal
Hazard

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Sold states
Nationwide in the USA
Affected count
21,930 Cartons
Manufactured in
400 Interpace Pkwy Bldg A, Parsippany, NJ, United States
Products
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9262-08.

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0406-2026

More Teva Pharmaceuticals USA, Inc recalls

Don't want to check this manually?

We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Get the Sunday Brief